XML 143 R76.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Acquisitions, investments, purchases of intangible assets and divestitures - Estimated Fair Values of Assets Acquired and Liabilities Assumed and Pro forma financial information (Details)
€ / shares in Units, $ / shares in Units, € in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2019
USD ($)
$ / shares
Dec. 31, 2019
EUR (€)
€ / shares
Dec. 31, 2019
EUR (€)
Dec. 31, 2018
EUR (€)
Dec. 31, 2017
EUR (€)
Estimated Fair Values of Assets Acquired and Liabilities Assumed Details          
Cash and cash equivalents | €     € 55,210 € 3,538 € 17,630
Intangible assets and other assets | €     685,047    
Goodwill | €     1,607,559 328,702  
Noncontrolling interests | €     € (65,217) € (45,319) € (14,293)
Revenue of acquiree since acquisition date | €   € 364,892      
Operating profit (loss) of acquiree since acquisition date | €   (68,599)      
NxStage Medical Inc          
Estimated Fair Values of Assets Acquired and Liabilities Assumed Details          
NxStage purchase per common share | $ / shares $ 30.00        
Cash and cash equivalents $ 47,203        
Trade accounts and other receivables 34,062        
Inventories 63,735        
Other current assets 15,819        
Property, plant and equipment 104,533        
Right-of-use assets 21,603        
Intangible assets and other assets 761,734        
Goodwill 1,201,613        
Accounts payable, current provisions and other current liabilities (72,429)        
Deferred taxes (100,485)        
Lease liabilities (22,065)        
Other liabilities (27,822)        
Noncontrolling interests (4,063)        
Total acquisition cost 2,023,438        
Cash acquired (47,203)        
Net cash paid $ 1,976,235 € 1,740,563      
Useful lives 13 years 13 years      
Revenue of acquiree since acquisition date $ 294,281 € 262,875      
Operating profit (loss) of acquiree since acquisition date (31,145) (27,821)      
Proforma financial information details          
Pro forma revenue | €   17,521,432      
Pro forma net income attributable to shareholders of FMC-AG & Co. KGaA | €   € 1,186,516      
Basic earnings per share | € / shares   € 3.92      
Diluted earnings per share | € / shares   € 3.92      
NxStage Medical Inc | Technology          
Estimated Fair Values of Assets Acquired and Liabilities Assumed Details          
Intangible assets and other assets $ 660,300